Cargando…

Latent tuberculosis infection treatment completion in Biscay: differences between regimens and monitoring approaches

INTRODUCTION: Contact tracing and treatment of latent tuberculosis infection (LTBI) is a key element of tuberculosis (TB) control in low TB incidence countries. A TB control and prevention program has been active in the Basque Country since 2003, including the development of the nurse case manager r...

Descripción completa

Detalles Bibliográficos
Autores principales: Ortiz Laza, N., Lopez Aranaga, I., Toral Andres, J., Toja Uriarte, B., Santos Zorrozua, B., Altube Urrengoechea, L., Garros Garay, J., Tabernero Huguet, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651218/
https://www.ncbi.nlm.nih.gov/pubmed/38020141
http://dx.doi.org/10.3389/fmed.2023.1265057
_version_ 1785135947423154176
author Ortiz Laza, N.
Lopez Aranaga, I.
Toral Andres, J.
Toja Uriarte, B.
Santos Zorrozua, B.
Altube Urrengoechea, L.
Garros Garay, J.
Tabernero Huguet, E.
author_facet Ortiz Laza, N.
Lopez Aranaga, I.
Toral Andres, J.
Toja Uriarte, B.
Santos Zorrozua, B.
Altube Urrengoechea, L.
Garros Garay, J.
Tabernero Huguet, E.
author_sort Ortiz Laza, N.
collection PubMed
description INTRODUCTION: Contact tracing and treatment of latent tuberculosis infection (LTBI) is a key element of tuberculosis (TB) control in low TB incidence countries. A TB control and prevention program has been active in the Basque Country since 2003, including the development of the nurse case manager role and a unified electronic record. Three World Health Organization-approved LTBI regimens have been used: isoniazid for 6 months (6H), rifampicin for 4 months (4R), and isoniazid and rifampicin for 3 months (3HR). Centralized follow-up by a TB nurse case manager started in January 2016, with regular telephone follow-up, telemonitoring of blood test results, and monitoring of adherence by electronic review of drugs dispensed in pharmacies. OBJECTIVE: To estimate LTBI treatment completion and toxicity of different preventive treatment regimens in a real-world setting. Secondary objective: to investigate the adherence to different approaches to preventive treatment monitoring. METHODS: A multicentre retrospective cohort study was conducted using data collected prospectively on contacts of patients with TB in five hospitals in Biscay from 2003 to 2022. RESULTS: A total of 3,066 contacts with LTBI were included. The overall completion rate was 66.8%; 86.5% of patients on 3HR (n = 699) completed treatment vs. 68.3% (n = 1,260) of those on 6H (p < 0.0001). The rate of toxicity was 3.8%, without significant differences between the regimens. A total of 394 contacts were monitored by a TB nurse case manager. In these patients, the completion rate was 85% vs. 67% in those under standard care (p < 0.001). A multivariate logistic regression model identified three independent factors associated with treatment completion: being female, the 3HR regimen, and nurse telemonitoring. CONCLUSION: 3HR was well tolerated and associated with a higher rate of treatment completion. Patients with nurse telemonitoring follow-up had better completion rates.
format Online
Article
Text
id pubmed-10651218
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106512182023-10-31 Latent tuberculosis infection treatment completion in Biscay: differences between regimens and monitoring approaches Ortiz Laza, N. Lopez Aranaga, I. Toral Andres, J. Toja Uriarte, B. Santos Zorrozua, B. Altube Urrengoechea, L. Garros Garay, J. Tabernero Huguet, E. Front Med (Lausanne) Medicine INTRODUCTION: Contact tracing and treatment of latent tuberculosis infection (LTBI) is a key element of tuberculosis (TB) control in low TB incidence countries. A TB control and prevention program has been active in the Basque Country since 2003, including the development of the nurse case manager role and a unified electronic record. Three World Health Organization-approved LTBI regimens have been used: isoniazid for 6 months (6H), rifampicin for 4 months (4R), and isoniazid and rifampicin for 3 months (3HR). Centralized follow-up by a TB nurse case manager started in January 2016, with regular telephone follow-up, telemonitoring of blood test results, and monitoring of adherence by electronic review of drugs dispensed in pharmacies. OBJECTIVE: To estimate LTBI treatment completion and toxicity of different preventive treatment regimens in a real-world setting. Secondary objective: to investigate the adherence to different approaches to preventive treatment monitoring. METHODS: A multicentre retrospective cohort study was conducted using data collected prospectively on contacts of patients with TB in five hospitals in Biscay from 2003 to 2022. RESULTS: A total of 3,066 contacts with LTBI were included. The overall completion rate was 66.8%; 86.5% of patients on 3HR (n = 699) completed treatment vs. 68.3% (n = 1,260) of those on 6H (p < 0.0001). The rate of toxicity was 3.8%, without significant differences between the regimens. A total of 394 contacts were monitored by a TB nurse case manager. In these patients, the completion rate was 85% vs. 67% in those under standard care (p < 0.001). A multivariate logistic regression model identified three independent factors associated with treatment completion: being female, the 3HR regimen, and nurse telemonitoring. CONCLUSION: 3HR was well tolerated and associated with a higher rate of treatment completion. Patients with nurse telemonitoring follow-up had better completion rates. Frontiers Media S.A. 2023-10-31 /pmc/articles/PMC10651218/ /pubmed/38020141 http://dx.doi.org/10.3389/fmed.2023.1265057 Text en Copyright © 2023 Ortiz Laza, Lopez Aranaga, Toral Andres, Toja Uriarte, Santos Zorrozua, Altube Urrengoechea, Garros Garay and Tabernero Huguet. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Ortiz Laza, N.
Lopez Aranaga, I.
Toral Andres, J.
Toja Uriarte, B.
Santos Zorrozua, B.
Altube Urrengoechea, L.
Garros Garay, J.
Tabernero Huguet, E.
Latent tuberculosis infection treatment completion in Biscay: differences between regimens and monitoring approaches
title Latent tuberculosis infection treatment completion in Biscay: differences between regimens and monitoring approaches
title_full Latent tuberculosis infection treatment completion in Biscay: differences between regimens and monitoring approaches
title_fullStr Latent tuberculosis infection treatment completion in Biscay: differences between regimens and monitoring approaches
title_full_unstemmed Latent tuberculosis infection treatment completion in Biscay: differences between regimens and monitoring approaches
title_short Latent tuberculosis infection treatment completion in Biscay: differences between regimens and monitoring approaches
title_sort latent tuberculosis infection treatment completion in biscay: differences between regimens and monitoring approaches
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651218/
https://www.ncbi.nlm.nih.gov/pubmed/38020141
http://dx.doi.org/10.3389/fmed.2023.1265057
work_keys_str_mv AT ortizlazan latenttuberculosisinfectiontreatmentcompletioninbiscaydifferencesbetweenregimensandmonitoringapproaches
AT lopezaranagai latenttuberculosisinfectiontreatmentcompletioninbiscaydifferencesbetweenregimensandmonitoringapproaches
AT toralandresj latenttuberculosisinfectiontreatmentcompletioninbiscaydifferencesbetweenregimensandmonitoringapproaches
AT tojauriarteb latenttuberculosisinfectiontreatmentcompletioninbiscaydifferencesbetweenregimensandmonitoringapproaches
AT santoszorrozuab latenttuberculosisinfectiontreatmentcompletioninbiscaydifferencesbetweenregimensandmonitoringapproaches
AT altubeurrengoecheal latenttuberculosisinfectiontreatmentcompletioninbiscaydifferencesbetweenregimensandmonitoringapproaches
AT garrosgarayj latenttuberculosisinfectiontreatmentcompletioninbiscaydifferencesbetweenregimensandmonitoringapproaches
AT tabernerohuguete latenttuberculosisinfectiontreatmentcompletioninbiscaydifferencesbetweenregimensandmonitoringapproaches